Clinical hold for MGTA The FDA is requiring that Magenta develop an additional bioassay to be used in conjunction with the PK/PD model to inform dose escalation decisions in addition to safety monitoring
"Don't worry about the world coming to an end today. It's already tomorrow in Australia"